Medical News

RSS

CFAR receives a five-year renewal grant to continue AIDS research

The Case Western Reserve University/University Hospitals Case Medical Center Center for AIDS Research announced today it has received a five-year renewal grant from the National Institutes of Health for $9 million. The CFAR provides clinical and technological support to researchers working on HIV-related projects at Case Western Reserve, University Hospital Case Medical Center, MetroHealth Medical Center, Cleveland Clinic, and several international sites.

22 Jul 2010

Today's OpEds: U.S. and AIDS; Mass. example on health reform?; Unions and health costs

George W. Bush made an impressive commitment to the international fight against AIDS when he formed the President's Emergency Plan for AIDS Relief program. … Thanks to these efforts — and similar initiatives ... the number of African patients with access to AIDS drugs jumped tenfold from 2003 to 2008. Since 2004, the AIDS-related mortality rate in sub-Saharan Africa has dropped 18 percent. Yet President Obama added only $366 million to the program this year — well below the $1 billion per year he promised to add when he was on the campaign trail (Desmond Tutu, 7/20).

22 Jul 2010

Surgery & physical therapy equally effective in knee ligament tears: study

A new study released this Wednesday compared intense physical therapy with surgery in common knee ligament injury and found that both techniques had similar outcomes.

21 Jul 2010

Avastin – breast cancer drug, fails to pass the FDA advisory panel vote on efficacy

According to a Food and Drug Administration (FDA) advisory committee’s (The Oncology Drugs Advisory Committee, or ODAC) recommendation this Tuesday, the marketing approval of the popular breast cancer drug, Avastin or Bevacizumab should be withdrawn.

21 Jul 2010

Vaginal birth after previous C-section may be a safe option say doctors

According to new practice guidelines revealed for obstetricians by the American College of Obstetricians and Gynecologists this Wednesday, a vaginal birth after a Caesarean section (VBAC) or maybe even after two C-sections can be a safe and appropriate choice.

21 Jul 2010

Quick-Med Technologies receives USPTO Notice of Allowance for key NIMBUS antimicrobial technology patent

Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a key patent related to the Company's proprietary NIMBUS® antimicrobial technology.

21 Jul 2010

Genzyme second-quarter revenue decreases to $1.08 billion

Genzyme Corp. today reported that second-quarter revenue was $1.08 billion, compared with $1.23 billion in the same period last year, reflecting limited shipments of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) due to product supply constraints in 2010. The company expects to be able to increase shipments of Cerezyme and Fabrazyme during the second half of the year.

21 Jul 2010

New findings suggest link between increased cholesterol, depression

Most people know that high cholesterol levels place them at increased risk for heart disease and stroke. Prior research has shown that particular types of strokes contribute to one's risk for depression, and that abnormal blood lipid levels can increase the risk of depression in the elderly.

21 Jul 2010

SensAble Technologies reports record dental sales for second-quarter 2010

SensAble Technologies Inc., a privately held provider of 3D modeling software, haptic devices and dental restoration design and fabrication solutions, announced that it achieved record dental sales during its second quarter ending June 30, driven by worldwide popularity of its integrated SensAble Dental Lab System (SDLS).

21 Jul 2010

Tethys Bioscience raises $33 million to drive market uptake of PreDx Diabetes Risk Score blood test

Tethys Bioscience, Inc., a privately held company, announced today that the company has recently raised $33 million, comprising $23 million of venture financing and a $10 million working capital loan. Participants in the venture financing included new investors Greenspring Associates, Inc. (formerly Montagu Newhall Associates, Inc.) and Paul Capital Investments, as well as current investors.

21 Jul 2010

Medicare Star Support Program launched to help Medicare Advantage plans boost star ratings

Health Dialog today announced that it has launched its Medicare Star Support Program to help Medicare Advantage plans boost their Health Plan Quality and Performance ("Star") Ratings and ensure that seniors are getting the best care possible. Star ratings are calculated by the Centers for Medicare & Medicaid Services and can range from 1 to 5, with 5 representing the highest quality.

21 Jul 2010

NIH awards KGI $3.6M grant to develop diagnostic assays and devices for multi-drug resistant tuberculosis

Keck Graduate Institute (KGI) Director of Research Angelika Niemz has been awarded a four-year, $3.6 million collaborative research grant from the National Institutes of Health (NIH).

21 Jul 2010

AMRI initiates enrollment for Phase I study of ALB-127158 for obesity

AMRI has commenced enrollment for a Phase I study of ALB-127158(a), a novel MCH1 receptor antagonist offering a potential new approach for the treatment of obesity. The announcement was made yesterday during a presentation by AMRI's Dr. Peter Guzzo, director, discovery research and development, at the 6th Obesity and Diabetes Drug Development Summit in Arlington, VA. Preclinical data were also reported.

21 Jul 2010

SPX announces completion of Anhydro acquisition

SPX Corporation today announced that it has completed the acquisition of the Anhydro business, a Soeborg, Denmark-based global supplier of liquid concentration equipment, powder processing solutions, and dewatering plants and equipment. The terms of the transaction were not disclosed.

21 Jul 2010

Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials

Shionogi-ViiV Healthcare LLC today announced that it will be progressing its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 ('572) into Phase III clinical trials. '572 will be the only once-daily, unboosted integrase inhibitor in Phase III clinical development.

21 Jul 2010

AB SCIEX and ETH partner to accelerate analysis and improve results for metabolomics

AB SCIEX, a global leader in life science analytical technologies, today announced that it is working with scientists at the ETH Zurich Institute of Molecular Systems Biology as part of the Swiss Systems Biology Program (SystemsX.ch) to accelerate analysis and improve results for metabolomics, which is the scientific study of chemical processes involving metabolites.

21 Jul 2010

Pharmarama ranked as Britain's 8th fastest-growing private company for overseas sales

Pharmarama International, a leader in strategically sourcing comparator medicines for clinical trials worldwide, today announced that it has been ranked as Britain's eighth fastest-growing private company for overseas sales in a 2010 survey published by the country's leading business newspaper, The Sunday Times.

21 Jul 2010

New insights on early pathogenic events, strategies for preventing HIV infection

In a plenary lecture at the 18th International AIDS conference in Vienna, Austria, Anthony S. Fauci, M.D., will present new insights on the early and complex pathogenic events that occur rapidly-within hours to days-following sexual exposure to HIV.

21 Jul 2010

NovaBay reports positive results from NVC-422 Phase 2a proof-of-concept clinical trial for impetigo

NovaBay Pharmaceuticals, Inc. today announced that its lead product candidate was safe and efficacious against the highly contagious skin infection impetigo in a Phase 2a proof-of-concept clinical trial. This dose-ranging study showed that the drug cleared impetigo infections, including those in the trial caused by a drug-resistant strain of bacteria called methicillin-resistant Staphylococcus aureus or MRSA. Impetigo afflicts approximately 1 million people, primarily infants and children, in the United States annually.

21 Jul 2010

PROLOR Biotech initiates Phase II clinical trial of biobetter version of human growth hormone

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced initiation of a Phase II clinical trial of hGH-CTP, the company's proprietary biobetter version of human growth hormone (hGH).

21 Jul 2010

Medical News

CFAR receives a five-year renewal grant to continue AIDS research

Today's OpEds: U.S. and AIDS; Mass. example on health reform?; Unions and health costs

Surgery & physical therapy equally effective in knee ligament tears: study

Avastin – breast cancer drug, fails to pass the FDA advisory panel vote on efficacy

Vaginal birth after previous C-section may be a safe option say doctors

Quick-Med Technologies receives USPTO Notice of Allowance for key NIMBUS antimicrobial technology patent

Genzyme second-quarter revenue decreases to $1.08 billion

New findings suggest link between increased cholesterol, depression

SensAble Technologies reports record dental sales for second-quarter 2010

Tethys Bioscience raises $33 million to drive market uptake of PreDx Diabetes Risk Score blood test

Medicare Star Support Program launched to help Medicare Advantage plans boost star ratings

NIH awards KGI $3.6M grant to develop diagnostic assays and devices for multi-drug resistant tuberculosis

AMRI initiates enrollment for Phase I study of ALB-127158 for obesity

SPX announces completion of Anhydro acquisition

Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials

AB SCIEX and ETH partner to accelerate analysis and improve results for metabolomics

Pharmarama ranked as Britain's 8th fastest-growing private company for overseas sales

New insights on early pathogenic events, strategies for preventing HIV infection

NovaBay reports positive results from NVC-422 Phase 2a proof-of-concept clinical trial for impetigo

PROLOR Biotech initiates Phase II clinical trial of biobetter version of human growth hormone

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Latest News